BR112018015480A2 - proteínas de ligação ao antígeno que se ligam a pd-l1 - Google Patents
proteínas de ligação ao antígeno que se ligam a pd-l1Info
- Publication number
- BR112018015480A2 BR112018015480A2 BR112018015480-6A BR112018015480A BR112018015480A2 BR 112018015480 A2 BR112018015480 A2 BR 112018015480A2 BR 112018015480 A BR112018015480 A BR 112018015480A BR 112018015480 A2 BR112018015480 A2 BR 112018015480A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding
- proteins
- antigen
- antigen binding
- higher yields
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
trata-se de anticorpos de classe igg anti-pd-l1 que têm capacidade aprimorada para serem fabricados com maiores rendimentos. de modo mais específico, revelam-se anticorpos humanos que se ligam a pd-l1, fragmentos de ligação a pd-l1 que podem ser fabricados com maiores rendimentos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662288912P | 2016-01-29 | 2016-01-29 | |
US62/288,912 | 2016-01-29 | ||
PCT/US2017/015429 WO2017132562A1 (en) | 2016-01-29 | 2017-01-27 | Antigen binding proteins that bind pd-l1 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018015480A2 true BR112018015480A2 (pt) | 2019-05-21 |
Family
ID=59386438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018015480-6A BR112018015480A2 (pt) | 2016-01-29 | 2017-01-27 | proteínas de ligação ao antígeno que se ligam a pd-l1 |
Country Status (16)
Country | Link |
---|---|
US (4) | US10118963B2 (pt) |
EP (1) | EP3408400B1 (pt) |
JP (3) | JP6883590B2 (pt) |
KR (1) | KR20190026642A (pt) |
CN (2) | CN116333124A (pt) |
AU (1) | AU2017212717B2 (pt) |
BR (1) | BR112018015480A2 (pt) |
CA (1) | CA3013051A1 (pt) |
CL (1) | CL2018002034A1 (pt) |
EA (1) | EA037855B1 (pt) |
IL (1) | IL260846B2 (pt) |
MX (2) | MX2018009228A (pt) |
PH (1) | PH12018501611A1 (pt) |
SG (1) | SG11201806496SA (pt) |
TW (1) | TWI760323B (pt) |
WO (1) | WO2017132562A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
JP6883590B2 (ja) | 2016-01-29 | 2021-06-09 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Pd−l1に結合する抗原結合性タンパク質 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
BR112020019116A2 (pt) * | 2018-03-22 | 2021-01-12 | Keires Ag | Proteínas de ligação, ácido nucleico, vetor, célula hospedeira, método de produção, proteína de ligação, composição farmacêutica e kit |
CN115991778A (zh) * | 2018-04-09 | 2023-04-21 | 原启生物科技(上海)有限责任公司 | 抗pd-l1抗体及其用途 |
CN117442717A (zh) | 2018-06-01 | 2024-01-26 | 大有华夏生物医药集团有限公司 | 治疗疾病或病况的组合物及其用途 |
WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
MX2021002077A (es) * | 2018-08-20 | 2021-05-27 | 1Globe Biomedical Co Ltd | Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer. |
US11124572B2 (en) | 2019-04-18 | 2021-09-21 | Qlsf Biotherapeutics Inc. | Humanized anti-PD-L1 antibodies |
CA3114467C (en) * | 2019-08-29 | 2024-06-11 | Remegen Co., Ltd. | Anti pd-l1 antibody and use thereof |
WO2022051414A1 (en) | 2020-09-02 | 2022-03-10 | Mayo Foundation For Medical Education And Research | Antibody-nanoparticle complexes and methods for making and using the same |
KR102557472B1 (ko) | 2020-11-16 | 2023-07-21 | 주식회사 이뮨온시아 | 면역항암제에 대한 치료 반응성을 예측하기 위한 바이오마커 및 이의 용도 |
CN117279948A (zh) | 2021-05-07 | 2023-12-22 | 益免安协公司 | 与cd47和pd-l1特异性结合的双特异性抗体 |
JP2024522623A (ja) | 2021-06-09 | 2024-06-21 | ソレント・セラピューティクス・インコーポレイテッド | リンパ管マイクロニードル送達デバイスを介した抗pd-1または抗pd-l1治療剤の投与によるがんの処置方法 |
WO2024064640A2 (en) * | 2022-09-19 | 2024-03-28 | Sonoma Biotherapeutics, Inc. | Citrullinated antigen-specific chimeric antigen receptors for targeting regulatory t cells to treat hidradenitis suppurativa |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
CA2140002A1 (en) | 1992-07-13 | 1994-01-20 | Jay Stout | A chemical method for selective modification of the n- and/or c-terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
PL2162149T3 (pl) | 2007-06-01 | 2014-04-30 | Henry M Jackson Found Advancement Military Medicine Inc | Szczepionka do zapobiegania nawrotowi raka sutka |
US8877688B2 (en) * | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
EP2903641A2 (en) | 2012-10-04 | 2015-08-12 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
EP3004169B1 (en) * | 2013-05-31 | 2023-03-22 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
JP6759104B2 (ja) * | 2014-04-04 | 2020-09-23 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 精密分子質量を用いた免疫グロブリンのアイソタイピング |
CN105238762A (zh) * | 2015-10-26 | 2016-01-13 | 无锡傲锐东源生物科技有限公司 | 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用 |
JP6883590B2 (ja) * | 2016-01-29 | 2021-06-09 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Pd−l1に結合する抗原結合性タンパク質 |
-
2017
- 2017-01-27 JP JP2018559164A patent/JP6883590B2/ja active Active
- 2017-01-27 BR BR112018015480-6A patent/BR112018015480A2/pt not_active Application Discontinuation
- 2017-01-27 CN CN202210999239.9A patent/CN116333124A/zh active Pending
- 2017-01-27 MX MX2018009228A patent/MX2018009228A/es unknown
- 2017-01-27 WO PCT/US2017/015429 patent/WO2017132562A1/en active Application Filing
- 2017-01-27 EP EP17745008.7A patent/EP3408400B1/en active Active
- 2017-01-27 US US15/418,514 patent/US10118963B2/en active Active
- 2017-01-27 SG SG11201806496SA patent/SG11201806496SA/en unknown
- 2017-01-27 CN CN201780021396.XA patent/CN109715821B/zh active Active
- 2017-01-27 EA EA201891709A patent/EA037855B1/ru unknown
- 2017-01-27 CA CA3013051A patent/CA3013051A1/en active Pending
- 2017-01-27 AU AU2017212717A patent/AU2017212717B2/en active Active
- 2017-01-27 KR KR1020187024978A patent/KR20190026642A/ko active Search and Examination
- 2017-02-02 TW TW106103519A patent/TWI760323B/zh active
-
2018
- 2018-07-27 MX MX2022011659A patent/MX2022011659A/es unknown
- 2018-07-27 CL CL2018002034A patent/CL2018002034A1/es unknown
- 2018-07-29 IL IL260846A patent/IL260846B2/en unknown
- 2018-07-30 PH PH12018501611A patent/PH12018501611A1/en unknown
- 2018-10-10 US US16/156,895 patent/US10919964B2/en active Active
-
2021
- 2021-01-13 US US17/148,450 patent/US11919952B2/en active Active
- 2021-03-22 JP JP2021047470A patent/JP7140867B2/ja active Active
-
2022
- 2022-04-15 JP JP2022067548A patent/JP2022095910A/ja active Pending
-
2024
- 2024-01-12 US US18/412,102 patent/US20240190959A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018015480A2 (pt) | proteínas de ligação ao antígeno que se ligam a pd-l1 | |
CY1120849T1 (el) | Αντισωμα που συνδεεται σε ανθρωπινο cd3 | |
DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
PH12018501042A1 (en) | Antibodies and antibody fragments for site-specific conjugation | |
AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
MX2015012540A (es) | Ratón de cadena ligera común. | |
UY37083A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso | |
EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EP3378871A4 (en) | PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF | |
BR112017006203A2 (pt) | anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune. | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
EP3176181A4 (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
EA201591806A1 (ru) | Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител | |
CR20150575A (es) | Anticuerpos humanos pac1 | |
BR112018012344A2 (pt) | anticorpos que se ligam especificamente a hla-dr e seus usos | |
AR105267A1 (es) | Anticuerpos de unión a tau | |
MX2016011809A (es) | Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos. | |
EP3573661A4 (en) | MONOVALENT ANTI-PROPERDINE ANTIBODIES AND ANTIBODY FRAGMENTS | |
WO2016023898A3 (en) | Intracellular antigen binding | |
DK3455261T3 (da) | Anti-ror2-antistoffer, antistoffragmenter, immunkonjugater deraf og anvendelser deraf | |
EP3587452A4 (en) | ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |